People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bryn Pharma, LLC | — | Pharma | Series C | $127.4M | $31.4M | 2025 |
James Borneman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Borneman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Marc Rapaport | 1 | 3 |
| William Humphries | 1 | 2 |
| Steven Hartman | 1 | 2 |
| Michael Kaseta | 1 | 2 |
| Michelle Lobel | 1 | 1 |
| Steven Killmeyer | 1 | 1 |
| Lisa Licht | 1 | 1 |
| Sandra Loreaux | 1 | 1 |
| Kate Soper Diaz | 1 | 1 |
| David Dworaczyk | 1 | 1 |
| Steve Killmeyer | 1 | 1 |
| Sandy Loreaux | 1 | 1 |
| Jim Borneman | 1 | 1 |
| Katherine Grell | 1 | 1 |
| Robert Yanez | 1 | 1 |
| Kate Grell | 1 | 1 |
| Dale Sander | 1 | 1 |
| Stephen Beckman | 1 | 1 |
| Rick Schaden | 1 | 1 |
| Anne Whitaker | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.